SerLect
SerLect Uses, Dosage, Side Effects, Food Interaction and all others data.
SerLect, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. It is a phenylindole derivative used in the treatment of schizophrenia. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market.
SerLect is an atypical antipsychotic at least as effective as haloperidol and risperidone in the treatment of neuroleptic-responsive schizophrenia. SerLect improves negative symptoms, and is also effective for the treatment of neuroleptic-resistant schizophrenia. SerLect is generally well tolerated and is associated with a low rate of extrapyramidal symptoms (EPS).
Trade Name | SerLect |
Generic | Sertindole |
Sertindole Other Names | Sertindol, Sertindole, Sertindolum |
Type | |
Formula | C24H26ClFN4O |
Weight | Average: 440.941 Monoisotopic: 440.177917386 |
Groups | Approved, Investigational, Withdrawn |
Therapeutic Class | |
Manufacturer | |
Available Country | |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
SerLect is an atypical antipsychotic indicated in the treatment of schizophrenia.
Used in the treatment of schizophrenia.
SerLect is also used to associated treatment for these conditions: Schizophrenia
How SerLect works
SerLect is an antipsychotic drug with affinity for dopamine D2, serotonin 5-HT2A and 5-HT2C, and alpha1-adrenoreceptors. Preclinical studies suggest that sertindole acts preferentially on limbic and cortical dopaminergic neurons and clinical trials have confirmed that sertindole is effective at a low dopamine D2 occupancy level.
Elimination Route
Orally available.
Half Life
3 days
Innovators Monograph
You find simplified version here SerLect